Emily Hanson, DO
Family Medicine · Murphysboro, ILNPI 1023083748
Payments from drug & device makers
Across 441 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$976
- AstraZeneca$954
- AbbVie$865
- GSK$544
- Amgen$416
- Novartis$299
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,136100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 56 | $976 |
| AstraZeneca | 60 | $954 |
| AbbVie(2 entities) | 53 | $865 |
| GSK | 38 | $544 |
| Amgen | 29 | $416 |
| Novartis | 18 | $299 |
| Boehringer Ingelheim | 17 | $287 |
| Johnson & Johnson | 19 | $245 |
| Pfizer | 13 | $228 |
| Novo Nordisk | 14 | $220 |
| Merck | 14 | $217 |
| Abbott | 11 | $190 |
| Astellas Pharma US Inc | 12 | $175 |
| Sumitomo Pharma America, Inc. | 10 | $175 |
| Bayer | 7 | $136 |
| Neurocrine Biosciences, Inc. | 6 | $133 |
| Nestle Healthcare Nutrition Inc. | 6 | $109 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $105 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| Dexcom, Inc. | 4 | $85 |
| Radius Health, Inc. | 3 | $77 |
| Aimmune Therapeutics, Inc. | 4 | $71 |
| Sunovion Pharmaceuticals Inc. | 5 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $69 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| Mylan Specialty L.p. | 4 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Viatris Specialty LLC | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 3 | $33 |
| Exact Sciences | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Seqirus USA Inc | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
How this compares
$7,136 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 119 | $132,008 |
| EliquisApixaban | 128 | $124,944 |
| OzempicSemaglutide | 96 | $109,656 |
| TrulicityDulaglutide | 88 | $98,598 |
| ZenpepLipase/Protease/Amylase | 12 | $56,578 |
| RybelsusSemaglutide | 34 | $50,793 |
| RexultiBrexpiprazole | 23 | $32,657 |
| FarxigaDapagliflozin Propanediol | 39 | $32,624 |
| MounjaroTirzepatide | 31 | $32,052 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $31,244 |
| TradjentaLinagliptin | 24 | $30,766 |
| MyrbetriqMirabegron | 44 | $28,814 |
| LinzessLinaclotide | 25 | $26,476 |
| XareltoRivaroxaban | 19 | $24,764 |
| JanuviaSitagliptin Phosphate | 30 | $23,959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $287 | $169,682155 claims |
| Novo NordiskOzempic, Rybelsus | $220 | $160,449130 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $976 | $130,651119 claims |
| PfizerEliquis | $228 | $124,944128 claims |
| Aimmune Therapeutics, Inc.Zenpep | $71 | $56,57812 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $954 | $54,23274 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $544 | $41,26361 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $94 | $32,65723 claims |
| MerckJanuvia, Belsomra | $217 | $32,50347 claims |
| Astellas Pharma US IncMyrbetriq | $175 | $28,81444 claims |
| AbbVieLinzess | $865 | $26,47625 claims |
| Johnson & JohnsonXarelto | $245 | $24,76419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Murphysboro
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.